Диссертация (1139742), страница 22
Текст из файла (страница 22)
795–802.157. Padhani A.R. et al. Dynamic contrast enhanced MRI of prostatecancer:correlation with morphology and tumour stage, histological grade andPSA // Clin. Radiol. — 2000. — Vol. 55. — P. 99–109.158. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics,2002 // CA Cancer J. Clin. — 2005. — Vol. 55. — №2. — P. 74–108.159. Partin A.W., Mangold L.A., Lamm D.M. et al.
Contemporary updateof prostate cancer staging nomograms (Partin Tables) for the new millennium //Urology. — 2001. — Vol. 58. — №2. — P. 843–848.160. Partin A.W., Kattan M.W., Subong E.N. et al.Combination ofprostate-specific antigen, clinical stage, and Gleason score to predict pathologicalstage of localized prostate cancer. A multi-institutional update // JAMA. —2002.
— Vol. 277. — Р. 1445–1451.161. Polascik, Thomas J., Imaging and Focal Therapy of Early ProstateCancer Humana Press, 2013, p. 396.165162. Prando A. et al. Prostatic biopsy directed with endorectal MRspectroscopic imaging findings in patients with elevated prostate specific antigenlevels and prior negative biopsy findings: early experience // Radiology. —2005. — Vol. 236. — №3. — P. 903–910.163. Pickles M.D., Gibbs P., Sreenivas M., Turnbull L.W. Diffusionweighted imaging of normal and ma¬lignant prostate tissue at 3.0 T // J. Magn.Reson. Imaging.
— 2006. — Vol. 23. — P. 130–134.164. Pohmann R., Von Kienlin M. Accurate phosphorus metabolite imagesof the human heart by 3D acquisition-weighted CSI // Magn. Reson. Med. —2001. — Vol. 45. — №5. — P. 817–826.165. Punglia R.S., D’Amico A.V., Catalona W.J. et al Effect of verificationbias on screening for prostate cancer by measurement of prostate-specific antigen //N. Engl. J.
Med. — 2003. — Vol. 349. — №4. — Р. 335–342.166. Qian J., Wollan P., Bostwick D.G. The extent and multicentricity ofhigh-grade prostatic intraepithelial neoplasia in clinically localized prostaticadenocarcinoma // Hum. Pathol. — 1997. — Vol. 28. — №2.
— P. 143–148.167. Ramon J., Denis L.J. Prostate cancer. — Berlin: Springer Verlag,2007. — P. 271.168. Reinsberg S.A., Payne G.S., Riches S.F. et al.Combined use ofdiffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostatecancer detection // Am. J. Roentgenol. — 2007. — Vol. 188. — №1. — P. 91–98.169. Ren J., Huan Y., Wang H.
et al. Seminal vesicle invasion in prostatecancer: prediction with combined T2-weighted and diffusion-weighted MRimaging // Eur. Radiol. — 2009. — Vol. 19. — №10. — P. 2481–2486.170. Ross R., Harisinghani M. Prostate cancer imaging — What theurologic oncologist needs to know // Radiol. Clin. N. Am. — 2006. — Vol. 44. —№5. — P. 711–722.166171. Roehl K.A., Antenor J.A., Catalona W.J.
Serial biopsy results inprostate cancer screening study // J. Urol. — 2002. — Vol. 167. — P. 2435–2479.172. Röthke M., Blondin D., Schlemmer H.P., Franiel T. PI-RADSClassification: Structured Reporting for MRI of the Prostate, Clinical Men’sHealth. — Berlin, Germany: MAGNETOM Flash, 2013. — P. 30–38.173. Rouviere O. IRM de la prostate: optimisation des protocolestechniques // J.
Radiol. — 2006. — Vol. 87. — №2. — P. 210–221.174. Rouviere O., Hartman R.P., Lyonnet D. Prostate MR imaging at highfield strength: evolution or revolution? // Eur. Radiol. — 2006. — Vol. 16. —Р. 276–284.175. Rutter A., Hugenholtz H., Saunders J.K. et al. One-dimensionalphosphorus-31 chemical shift imaging of human brain tumors // Invest. Radiol. —1995. — Vol. 30.
— №6. — P. 359–366.176. Saito K., Kaminaga T., Muto S. et al. Clinical efficacy of protonmagnetic resonance spectroscopy (1H-MRS) in the diagnosis of localized prostatecancer // Anticancer Res. — 2008. — Vol. 28. — №3B. — Р. 1899–1904.177. Sala E., Akin O., Moskowitzetal C.S. Endorectal MR imaging in theevaluation of seminal vesicle invasion: diagnostic accuracy and multivariatefeature analysis // Radiology.
— 2006. — Vol. 238. — №3. — P. 929–937.178. Sato C., Naganawa S., Nakamura T. et al. Differentiationofnoncancerous tissue and cancer lesions by apparent diffusion coefficient valuesin transition and peripheral zones of the prostate // J. Magn. Reson. Imaging. —2005. — Vol.
21. — P. 258–262.179. Sciarra A., Panebianco V., Ciccariello M. et al.Magnetic resonancespectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magneticresonance (DCE-MRI): pattern changes from inflammation to prostate cancer //Cancer Invest. — 2010. — Vol. 28. — №4. — P. 424–432.167180. Sciarra A., Barentsz J., Bjartell A. et al. Advances in magneticresonance imaging: how they are changing management of prostate cancer // Eur.Urol. — 2011. — Vol.
59. — Р. 962–977.181.Sim H.G., Cheng C.W. Changing demography of prostate cancer inAsia // Eur. J. Cancer. — 2005. — Vol. 41. — №6. — P. 834–845.182. Stewart B.W., Kleihues P. Le cancer dans le monde. — Lyon: IARCPress, 2005. — P.364.183. Scheenen T.W., Klomp D.W., Roll S.A. et al. Fast acquisitionweighted threedimensional proton MR spectroscopic imaging of the humanprostate // Magn.
Reson. Med. — 2004. — Vol. 52. — №1. — P. 80–88.184. Scheenen T.W., Weiland E., Futterer J.J. et al. Preliminary results ofIMAPS : an international multi-centre assessment of prostate MR spectroscopy / 7Proceedings of the 13th meeting of the International society for magneticresonance in med.— Berkeley, California: International society for magneticresonance in medicine, 2005. — P. 153.185. Scheidler J., Hricak H., Vigneron D.B. et al. Prostate cancer:localization with three-dimensional proton MR spectroscopic imaging —clinicopathologic study // Radiology. — 1999.
— Vol. 213. — №2. — P. 473–480.186. Schnall M., Lenkinski B., Milestone B. et al. Localized 1Hspectroscopy of the human prostate in-vivo / Society for magnetic resonance inmed. — Berkeley, California: International society for magnetic resonance inmedicine, 1990. — Vol.
1. — P. 288.187. Seltzer S.E., Getty D.J., Tempany CM. et al. Staging prostate cancerwith MR imaging: a combined radiologist-computer system // Radiology. —1997. — Vol. 202. — №1. — P. 219–226.188. Shimofusa R., Fujimoto H., Akamata H., Motoori K., Yamamoto S.,Ueda T., Ito H. Diffusion-weighted imaging of prostate cancer // J. Comput. Assist.Tomogr.
— 2005. — Vol. 29. — P. 149–153.168189. Shukla-Dave A., Hricak A., Eberhardt S.C. et al. Chronic prostatitis:MR imaging and III MR spectroscopic imaging findings — initial observations //Radiology. — 2004. — Vol. 231. — №3. — P. 717–724.190. Sijens P.E., Knopp M.V., Brunetti A. et al. III MR spectroscopy inpatients with metastatic bram tumors: a multicenter study // Magn.
Reson. Med. —1995. — Vol. 33. — №6. — P. 818–826.191. Sinha S., Sinha U. In vivo diffusion tensor imaging of the humanprostate // Magn. Reson. Med. — 2004. — Vol. 52. — P. 530–537.192. Swanson M.G., Vigneron D.B., Tran Т.К. et al. Single-voxeloversampled J-resolved spectroscopy of in vivo human prostate tissue // Magn.Reson. Med. — 2001. — Vol. 45. — №6. — P. 973–980.193. Swindle P., McCredie S., Russell P.
et al. Pathologic characterizationof human prostate tissue with proton MR spectroscopy // Radiology.— 2003. —Vol. 228. — №l. — P. 144–151.194. Thomas M.A., Narayan P., Kurhanewicz J. et al. 1H MR spectroscopyof normal and malignant human prostates in vivo // J. Magn. Reson. — 1990. —Vol. 87. — P.
610–619.195. Toyoda K., Kitai S., Ida M. et al. Usefulness of high-b-valuediffusion-weighted imagingin acute cerebral infarction // Eur. Radiol. — 2007. —Vol. 17. — №5. — Р. 1212–1220.196. Umbehr M., Kessler T.M., Sulser T. et al. Combined magneticresonance spectroscopy imaging in the diagnosis of prostate cancer: a systematicreview and meta-analysis // Eur.
Urol. — 2009. — Vol. 55. — №3. — Р. 575–590.197. Van der Graаff M., Schipper R.G. MRS of prostatic tissue focussed onthe detection of spermine, a possible biomarker of malignant behaviour in prostatecancer. — Berkeley, California: Society of magnetic resonance in medicine,1998.
— P. 613.169198. Van der Graaf M., Schipper R.G., Oosterhof G.O. et al. Proton MRspectroscopy of prostatic tissue focused on the detection of spermine, a possiblebiomarker of malignant behavior in prostate cancer // MAGMA. — 2000. —Vol. 10. — №3. — P. 153–159.199. Walsh P.C., Gittes R.F., Perlmutter A.P. et al. Benign prostatichyperplasia / Campbell's urology. — Philadelphia, Pa: Saunders, 1986.
— P.1248–1265.200. Wang L., Mullerad M., Chen H.N. et al. Prostate Cancer: IncrementalValue of Endorectal MR Imaging Findings for Prediction of ExtracapsularExtension // Radiology. — 2004. — Vol. 232. — P. 133–139.201. Wang L., Mazaheri Y., Zhang J. et al. Assessment of biologicaggressiveness of prostate cancer: correlation of MR signal intensity with Gleasongrade after radical prostatectomy // Radiology. — 2008. — Vol. 246.
— №1. —P. 168–176.202. Wang W., Epstein J.I. Small carcinoma of the prostate. A morphologicand immunohistochemical study 0f 95 cases // Am. J. Surg. Pathol. — 2008. —Vol. 32. — №1. — P. 65–71.203. Wein A.J., Kavoussi L.R., Novick A.C. et al. Campbell-WalshUrology. — 9th ed. — Philadelphia, PA: Saunders Elsevier, 2007. — 765 p.204. . Wittekind C., Greene F.L., Hutter R.V.P., Klimpfinger M.,Sobin L.H. TNM Atlas.
— 5th ed. (2 printing corrected). — Berlin: Springer,2007. — P.283–291.205. Young R.H., Srigley J.R., Amin M.B. et al.Tumors of the prostategland, seminal vesicles, male urethra and penis. Atlas of tumor pathology. Thirdseries. — Washington: Armed Forces Institute of Pathology, 2000. — 495 p.206. Yu K.K., Scheidler J., Hricak H. et al. Prostate cancer: prediction ofextracapsular extension with endorectal MR imaging and three-dimensional protonMR spectroscopic imaging // Radiology.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
